This company listing is no longer active
SHE Stock Overview
Through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Shedir Pharma Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.88 |
| 52 Week High | €4.98 |
| 52 Week Low | €3.34 |
| Beta | 0.72 |
| 1 Month Change | 0.41% |
| 3 Month Change | 32.61% |
| 1 Year Change | 7.96% |
| 3 Year Change | 12.96% |
| 5 Year Change | -10.62% |
| Change since IPO | -29.88% |
Recent News & Updates
Recent updates
Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Nov 08
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem
Oct 05Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?
Apr 06What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 30
Shareholder Returns
| SHE | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | 1.6% |
| 1Y | 8.0% | -2.6% | 17.2% |
Return vs Industry: SHE exceeded the Italian Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: SHE underperformed the Italian Market which returned 15% over the past year.
Price Volatility
| SHE volatility | |
|---|---|
| SHE Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.8% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: SHE has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: SHE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 84 | Antonio Scala | www.shedirpharma.com |
Shedir Pharma Group S.p.A., through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy. It provides products for andrological, cardiovascular, dermatological, hematological, energy, gastrointestinal, gynecological, metabolic, neurological, dental, ophthalmic, osteoarticular, otologic, respiratory, and trichological diseases. The company offers its products through a network of sales agents, wholesalers, and pharmacies.
Shedir Pharma Group S.p.A. Fundamentals Summary
| SHE fundamental statistics | |
|---|---|
| Market cap | €55.45m |
| Earnings (TTM) | €6.00m |
| Revenue (TTM) | €60.96m |
9.2x
P/E Ratio0.9x
P/S RatioIs SHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHE income statement (TTM) | |
|---|---|
| Revenue | €60.96m |
| Cost of Revenue | €42.05m |
| Gross Profit | €18.91m |
| Other Expenses | €12.91m |
| Earnings | €6.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 31.02% |
| Net Profit Margin | 9.84% |
| Debt/Equity Ratio | 7.3% |
How did SHE perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/24 11:47 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shedir Pharma Group S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gian Gadini | Banca Akros S.p.A. (ESN) |
| Maria Di Grado | KT & Partners Srl |